The efficacy of intrauterine misoprostol during cesarean section in prevention of primary PPH, a randomized controlled trial
- PMID: 30176758
- DOI: 10.1080/14767058.2018.1519796
The efficacy of intrauterine misoprostol during cesarean section in prevention of primary PPH, a randomized controlled trial
Abstract
Background: Postpartum hemorrhage is the leading cause of maternal mortality worldwide.Aim: To compare the incidence of postpartum hemorrhage in women eligible for elective cesarean section (CS) delivery when using intrauterine misoprostol added to oxytocin versus oxytocin alone.Design, Setting, Participants: This parallel randomized controlled trial study was conducted in two institutions in Egypt (Kasralainy and Aljazeerah hospital) 0.300 women eligible for elective CS delivery were enrolled in the study.Interventions: Before randomization, all women received the same preparations. After randomization; in the study group (N = 150), intrauterine misoprostol was used after placental delivery. In the control group (N = 150), the routine oxytocin alone was used.Results: Both groups were comparable (p-value >.05) with regard to the age, BMI, and gestational age as well as hemoglobin and hematocrit levels. The incidence of postpartum hemorrhage was significantly lower (p = .018) in the study group (1.33%) than the control group (6.67%). The absolute risk reduction was 5.3% (CI 95%: 0.8-10.6%) with a relative risk of 0.20 (CI 95%: 0.05-0.90) and number needed to treat (NNT) 19 (CI 95%: 125-9). Moreover, the needs for a blood transfusion, extra uterotonics or additional interventions were significantly lower in the study group than in the control group (p < .05). All the three parameters of blood loss ie the mean blood loss, and the mean reductions of hemoglobin and hematocrit levels were significantly (p-value <.05) lower in the study group (mean and SD) (442.59 and 151.33 mL,0.46 and 0.3 g/dL, and 0.84 and 0.56%), respectively than in the control group (591.01 and 287.97 mL,1.2 and 1.39 g/dL, and 3.47 and 3.52%), respectively. Adverse events were comparable between groups; these were fever, nausea, and vomiting and shivering.Conclusion: Intrauterine misoprostol (400 mg) when added to oxytocin is safe and effective in decreasing the incidence of postpartum hemorrhage (PPH) and reducing the amount of postpartum blood loss in case of elective CS delivery.
Keywords: PPH; extra uterotonics; intrauterine; misoprostol; oxytocin.
Similar articles
-
Comparative study between the roles of intrauterine misoprostol versus the sublingual route for prevention of postpartum blood loss in elective cesarean sections: a randomized controlled trial.BMC Pregnancy Childbirth. 2024 Oct 29;24(1):710. doi: 10.1186/s12884-024-06889-y. BMC Pregnancy Childbirth. 2024. PMID: 39472831 Free PMC article. Clinical Trial.
-
Sublingual misoprostol versus intramuscular oxytocin for prevention of postpartum hemorrhage in Uganda: a double-blind randomized non-inferiority trial.PLoS Med. 2014 Nov 4;11(11):e1001752. doi: 10.1371/journal.pmed.1001752. eCollection 2014 Nov. PLoS Med. 2014. PMID: 25369200 Free PMC article. Clinical Trial.
-
The effect of intrauterine misoprostol on blood loss during caesarean section.J Obstet Gynaecol. 2019 Aug;39(6):753-756. doi: 10.1080/01443615.2019.1581743. Epub 2019 Apr 22. J Obstet Gynaecol. 2019. PMID: 31010345
-
Comparison of the effects and side effects of misoprostol and oxytocin in the postpartum period: A systematic review.Taiwan J Obstet Gynecol. 2019 Nov;58(6):748-756. doi: 10.1016/j.tjog.2019.09.004. Taiwan J Obstet Gynecol. 2019. PMID: 31759522
-
Intravenous oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery: a systematic review and meta-analysis.Am J Obstet Gynecol. 2021 Sep;225(3):250.e1-250.e38. doi: 10.1016/j.ajog.2021.04.258. Epub 2021 May 4. Am J Obstet Gynecol. 2021. PMID: 33957113
Cited by
-
The effect of oxytocin, sublingual, and intrauterine misoprostol on blood loss in cesarean delivery: A randomized clinical trial.Eur J Obstet Gynecol Reprod Biol X. 2025 Feb 3;25:100369. doi: 10.1016/j.eurox.2025.100369. eCollection 2025 Mar. Eur J Obstet Gynecol Reprod Biol X. 2025. PMID: 39995616 Free PMC article.
-
Optimal dose of misoprostol combined with oxytocin for preventing postpartum hemorrhage in cesarean section: A randomised controlled trial.Ann Med Surg (Lond). 2022 Jun 4;78:103931. doi: 10.1016/j.amsu.2022.103931. eCollection 2022 Jun. Ann Med Surg (Lond). 2022. PMID: 35734671 Free PMC article.
-
Cohort Study Summary of the Effects of Carboprost Tromethamine Combined with Oxytocin on Infant Outcome, Postpartum Hemorrhage and Uterine Involution of Parturients Undergoing Cesarean Section.Comput Math Methods Med. 2022 Aug 25;2022:2233138. doi: 10.1155/2022/2233138. eCollection 2022. Comput Math Methods Med. 2022. Retraction in: Comput Math Methods Med. 2023 Dec 6;2023:9874735. doi: 10.1155/2023/9874735. PMID: 36060654 Free PMC article. Retracted. Clinical Trial.
-
Comparative study between the roles of intrauterine misoprostol versus the sublingual route for prevention of postpartum blood loss in elective cesarean sections: a randomized controlled trial.BMC Pregnancy Childbirth. 2024 Oct 29;24(1):710. doi: 10.1186/s12884-024-06889-y. BMC Pregnancy Childbirth. 2024. PMID: 39472831 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical